Drug intelligence / Profile preview

V1007X

Development stage: Preclinical
Lead developer: zyvran pharmaceuticals

Overview

**V1007X** is a Zyvran Pharmaceuticals investigational combination-drug program listed for **Alzheimer's disease** and **dementia with Lewy bodies**. Publicly available pipeline information does not disclose the constituent active ingredients, dosage form, route of administration, molecular targets, or specific pharmacologic mechanism. The program is therefore best characterized as an early disclosed neurodegenerative-disease combination therapy with an unspecified development phase.

Beyond the preview

Go deeper on V1007X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V1007X.

Explore the full profile